Randomized controlled trials are the cornerstone for reliably evaluating therapeutic strategies.
1 However, during the past 25 years, the rules and regulations governing randomized trials and their interpretation have become increasingly burdensome,
2 and the cost and complexity of trials has become prohibitive.
3 The present model is unsustainable, and the development of potentially effective treatments is often stopped prematurely on financial grounds, while existing drug treatments or non-drug interventions (such as screening strategies or management tools) may not be assessed reliably. The current ‘best regulatory practice’ environment, and a lack of consensus on what that requires, too often makes it unduly difficult to undertake efficient randomized trials able to provide reliable evidence about the safety and efficacy of potentially valuable interventions. Inclusion of underrepresented population groups and lack of diversity also remain among the challenges.